Tesamorelin Research for Fatty Liver Disease
An evidence-based overview of research examining Tesamorelin in the context of fatty liver disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin has shown remarkable efficacy in reducing hepatic fat in clinical trials, with Phase 2 data demonstrating a 37% relative reduction in liver fat fraction (HFF) compared to placebo. In treated patients, 35% achieved HFF below 5% (normalized), versus only 4% with placebo.
Beyond fat reduction, tesamorelin prevented fibrosis progression in NAFLD/NASH patients, suggesting potential disease-modifying effects. Hepatic transcriptomic analysis revealed improved oxidative phosphorylation and decreased inflammatory markers.
The FDA approved Phase 3 NASH development in December 2020 for patients with biopsy-confirmed NASH, and trials are ongoing. If successful, tesamorelin could become a first-in-class approved therapy for this liver disease.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Fatty Liver Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.